ARCHIVES

Hagop Kantarjian: Why Drugs Cost Too Much and How Prices Can be Brought Down

This article is from The Cancer Letter archive.

Vol. 39 No. 22 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

In Brief: House, Senate Enact FY ’92 Budget Bills For NCI That Differ By $200 Million; Senate’s Is Higher

September 27, 1991

Pharmacogenomics May Lead To Individualized Treatment

June 25, 2004

Study: BRCA2-Negative Women Could Still Have High Risk

December 27, 2013

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

Letter to the Editor

March 21, 2003